- Home
- MRNA vs BDX Comparison
MRNA vs BDX Comparison
Compare MRNA & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | BDX |
|---|---|---|
| Founded | 2010 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 49.4B |
| IPO Year | 2018 | 1998 |
Fundamental Metrics
Financial Performance| Metric | MRNA | BDX |
|---|---|---|
| Price | $198.47 | $180.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $34.27 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 13.5M | 1.5M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ 1.59 |
| Revenue | $19,263,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $15.43 | $3.02 |
| P/E Ratio | ★ N/A | $115.62 |
| Revenue Growth | 4.29 | ★ 8.24 |
| 52 Week Low | $22.28 | $140.11 |
| 52 Week High | $202.67 | $213.08 |
Technical Indicators
Market Signals| Indicator | MRNA | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 75.87 | 48.62 |
| Support Level | $43.35 | $175.20 |
| Resistance Level | N/A | $186.99 |
| Average True Range (ATR) | 11.47 | 3.61 |
| MACD | 2.59 | -0.51 |
| Stochastic Oscillator | 86.71 | 47.86 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About BDX Becton Dickinson and Company
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.